Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xuanzhu Biopharm

Request full access

An international innovative drug research and development company

Dongcheng District, ChinaFounded 2002Biotech & Life Sciences

About Xuanzhu Biopharm

Xuanzhu Biopharm, an innovative drug subsidiary of Sihuan Pharmaceutical Holdings Group, operates as a clinical-stage biopharmaceutical company with a strategic focus on significant disease areas including oncology, digestive health, and metabolic diseases like non-alcoholic steatohepatitis (NASH). Founded in 2002, the company has established a comprehensive research and development platform to create and commercialize Class 1 drugs, addressing unmet clinical needs in China and globally. The company's business model is centered on the independent R&D, production, and eventual commercialization of its drug pipeline. Xuanzhu Biopharm has been actively pursuing capital, having raised ¥610.5 million ($96 million) in a Series B round in January 2022 and attempting an IPO on the Hong Kong Stock Exchange.

The company's product development strategy is driven by dual R&D platforms in small molecule chemistry and large molecule biologics. This has resulted in a robust pipeline of over ten drug assets, featuring small molecules, monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). A key milestone was achieved in June 2023 when its small-molecule drug, Anaprozole Sodium, received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of duodenal ulcers. This was the first drug approved for marketing by Xuanzhu Biopharm, marking its transition from a pure R&D entity to a commercial-stage company. The market for this drug is substantial, with oral proton pump inhibitors in China representing a nearly RMB 13 billion market.

In its oncology pipeline, Xuanzhu Biopharm is advancing multiple candidates, with a particular focus on breast cancer. Its CDK4/6 inhibitor, Birociclib (XZP-3287), is a significant asset, with a New Drug Application (NDA) accepted by the NMPA for treating advanced breast cancer. The company is also developing XZP-3621 for lung cancer, with an expected regulatory decision in 2025. To bolster its large-molecule capabilities, Xuanzhu Biopharm acquired Beijing Combio Pharmaceutical in 2021, integrating antibody technology platforms. Despite its clinical progress, the company has faced financial challenges, reporting net losses due to the high costs of drug development.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
23.0/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2022 $84M $662M Efung Capital · Zhongji Investment · TJ Capital · SDIC Taikang Trust ↗
SERIES AOther financing Aug 2020 $132M $530M State Development & Investment Corporation (SDIC) —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Xuanzhu Biopharm website traffic

Latest recorded traffic for Xuanzhu Biopharm is 200 monthly website visits, down 37.5% over the last three months.

Latest monthly visits200 3-month web change-37.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Xuanzhu Biopharm in the Dongcheng District ecosystem

Live from Dealroom

The Xuanzhu Biopharm office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A13 investors entered at this stage

  • State Development & Investment Corporation (SDIC)
  • Sunshine Insurance Group Co
  • Efung Capital
  • Zhongji Investment
  • TJ Capital
  • SDIC Taikang Trust
  • BOC Capital
  • Shaanxi Financial Holding Group
  • Hainan Wanxin Private Equity Fund Management
  • DNV capital
  • Haichuang Funds of Funds
  • Huayi Capital
  • Jinjiang Xuanhong Equity Investment
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Dongcheng District HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xuanzhu Biopharm on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xuanzhu Biopharm’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.